Aptamer oligonucleotides: Novel potential therapeutic agents in autoimmune disease

Nucleic Acid Therapeutics

Volumn 25, Issue 4, 2015, Pages 173-179

  Li, Weibin ^a   Lan, Xiaopeng ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

APTAMER; INTERLEUKIN 17; IMMUNOLOGIC FACTOR; SINGLE STRANDED DNA;

AUTOIMMUNE DISEASE; DIABETES MELLITUS; HUMAN; MULTIPLE SCLEROSIS; MYASTHENIA GRAVIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; TH17 CELL; ARTHRITIS, RHEUMATOID; AUTOIMMUNITY; CHEMISTRY; DRUG EFFECTS; DRUG STABILITY; HYDROGEN BOND; LUPUS ERYTHEMATOSUS, SYSTEMIC; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; STATIC ELECTRICITY; SYNTHESIS; SYSTEMATIC EVOLUTION OF LIGANDS BY EXPONENTIAL ENRICHMENT APTAMER TECHNIQUE;

APTAMERS, NUCLEOTIDE; ARTHRITIS, RHEUMATOID; AUTOIMMUNITY; DIABETES MELLITUS; DNA, SINGLE-STRANDED; DRUG STABILITY; HUMANS; HYDROGEN BONDING; IMMUNOLOGIC FACTORS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MOLECULAR TARGETED THERAPY; MULTIPLE SCLEROSIS; MYASTHENIA GRAVIS; SELEX APTAMER TECHNIQUE; STATIC ELECTRICITY;

EID: 84937720346     PISSN: 21593337     EISSN: 21593345     Source Type: Journal    
DOI: 10.1089/nat.2014.0529     Document Type: Review

References (54)

1. Tuerk C, and L. Gold. (1990). Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 249: 505-510
2. Ellington AD, and J.W. Szostak. (1990). In vitro selection of RNA molecules that bind specific ligands. Nature 346: 818-822
3. Stoltenburg R, C. Reinemann, and B. Strehlitz. (2007). SELEX-A (r)evolutionary method to generate high-Affinity nucleic acid ligands. Biomol Eng 24: 381-403
4. Que-Gewirth NS, and B.A. Sullenger. (2007). Gene therapy progress, and prospects: RNA aptamers. Gene Ther 14: 283-291
5. Han K, Z. Liang, and N. Zhou. (2010). Design strategies for aptamer-based biosensors. Sensors (Basel) 10: 4541-4557
6. Dollins CM, S. Nair, and B.A. Sullenger. (2008). Aptamers in immunotherapy. Hum Gene Ther 19: 443-450
7. Li W, K. Wang, M. Zhao, X. Yang, M. Chen, and X. Lan. (2014). Development of aptamer oligonucleotides as anticoagulants, and antithrombotics for cardiovascular diseases: current status. Thromb Res 134: 769-773
8. Ng EW, D.T. Shima, P. Calias, E.T. Cunningham, Jr, D.R. Guyer, and A.P. Adamis. (2006). Pegaptanib, a. targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov 5: 123-132
9. Whatley AS, M.A. Ditzler, M.J. Lange, E. Biondi, A.W. Sawyer, J.L. Chang, J.D. Franken, and D.H. Burke. (2013). Potent inhibition of HIV-1 reverse transcriptase, and replication by nonpseudoknot, "UCAA-motif" RNA aptamers. Mol Ther Nucleic Acids 2: e71
10. Wang J, M. You, G. Zhu, M.I. Shukoor, Z. Chen, Z. Zhao, M.B. Altman, Q. Yuan, Z. Zhu, et al. (2013). Photosensitizer-gold nanorod composite for targeted multimodal therapy. Small 9: 3678-3684
11. Jalalian SH, S.M. Taghdisi, H.N. Shahidi, S.A. Kalat, P. Lavaee, M. Zandkarimi, N. Ghows, M.R. Jaafari, S. Naghibi, et al. (2013). Epirubicin loaded super paramagnetic iron oxide nanoparticle-Aptamer bioconjugate for combined colon cancer therapy, and imaging in vivo. Eur J Pharm Sci 50: 191-197
12. Lee MS. (2014). Role of innate immunity in the pathogenesis of type 1, and type 2 diabetes. J Korean Med Sci 29: 1038-1041
13. Jiang G, and B.B. Zhang. (2003). Glucagon, and regulation of glucose metabolism. Am J Physiol Endocrinol Metab 284: E671-E678
14. Lee Y, M.Y. Wang, X.Q. Du, M.J. Charron, and R.H. Unger. (2011). Glucagon receptor knockout prevents insulindeficient type 1 diabetes in mice. Diabetes 60: 391-397
15. Lee Y, E.D. Berglund, M.Y. Wang, X. Fu, X. Yu, M.J. Charron, S.C. Burgess, and R.H. Unger. (2012). Metabolic manifestations of insulin deficiency do not occur without glucagon action. Proc Natl Acad Sci U S A 109: 14972-14976
16. Kong HY, and J. Byun. (2013). Nucleic acid aptamers: new methods for selection, stabilization, and application in biomedical science. Biomol Ther (Seoul) 21: 423-434
17. Vater A, S. Sell, P. Kaczmarek, C. Maasch, K. Buchner, E. Pruszynska-Oszmalek, P. Kolodziejski, W.G. Purschke, K.W. Nowak, M.Z. Strowski, and S. Klussmann. (2013) A mixed mirror-image DNA/RNA aptamer inhibits glucagon, and acutely improves glucose tolerance in models of type 1, and type 2 diabetes. J Biol Chem 288: 21136-21147
18. Forsayeth JR, A. Montemurro, B.A. Maddux, R. DePirro, and I.D. Goldfine. (1987). Effect of monoclonal antibodies on human insulin receptor autophosphorylation, negative cooperativity, and down-regulation. J Biol Chem 262: 4134-4140
19. Doudna JA, T.R. Cech, and B.A. Sullenger. (1995). Selection of an RNA molecule that mimics a major autoantigenic epitope of human insulin receptor. Proc Natl Acad Sci U S A 92: 2355-2359
20. Lee SW, and B.A. Sullenger. (1996). Isolation of a nucleaseresistant decoy RNA that selectively blocks autoantibody binding to insulin receptors on human lymphocytes. J Exp Med 184: 315-324
21. Sayyed SG, H. Hagele, O.P. Kulkarni, K. Endlich, S. Segerer, D. Eulberg, S. Klussmann, and H.J. Anders. (2009). Podocytes produce homeostatic chemokine stromal cell-derived factor-1/CXCL12, which contributes to glomerulosclerosis, podocyte loss, and albuminuria in a mouse model of type 2 diabetes. Diabetologia 52: 2445-2454
22. Darisipudi MN, O.P. Kulkarni, S.G. Sayyed, M. Ryu, A. Migliorini, C. Sagrinati, E. Parente, A. Vater, D. Eulberg, et al. (2011). Dual blockade of the homeostatic chemokine CXCL12, and the proinflammatory chemokine CCL2 has additive protective effects on diabetic kidney disease. Am J Pathol 179: 116-124
23. Rodriguez M, A. Siva, J. Ward, K. Stolp-Smith, P O'Brien, and L. Kurland. (1994). Impairment, disability, and handicap in multiple sclerosis: a population-based study in Olmsted County, Minnesota. Neurology 44: 28-33
24. Bates D. (2011). Treatment effects of immunomodulatory therapies at different stages of multiple sclerosis in shortterm trials. Neurology 76: S14-S25
25. Muramatsu T. (2002). Midkine, and pleiotrophin: two related proteins involved in development, survival, inflammation, and tumorigenesis. J Biochem 132: 359-371
26. Maruyama K, H. Muramatsu, N. Ishiguro, and T. Muramatsu. (2004). Midkine, a. heparin-binding growth factor, i.s. fundamentally involved in the pathogenesis of rheumatoid arthritis. Arthritis Rheum 50: 1420-1429
27. Liu X, G.A. Mashour, H.F. Webster, and A. Kurtz. (1998). Basic FGF, and FGF receptor 1 are expressed in microglia during experimental autoimmune encephalomyelitis: temporally distinct expression of midkine, and pleiotrophin. Glia 24: 390-397
28. Viglietta V, C. Baecher-Allan, H.L. Weiner, and D.A. Hafler. (2004). Loss of functional suppression by CD4 + CD25 +regulatory T cells in patients with multiple sclerosis. J Exp Med 199: 971-979
29. Wang J, H. Takeuchi, Y. Sonobe, S. Jin, T. Mizuno, S. Miyakawa, M. Fujiwara, Y. Nakamura, T. Kato, et al. (2008). Inhibition of midkine alleviates experimental autoimmune encephalomyelitis through the expansion of regulatory T cell population. Proc Natl Acad Sci U S A 105: 3915-3920
30. Warrington AE, K. Asakura, A.J. Bieber, B. Ciric, V. Van Keulen, S.V. Kaveri, R.A. Kyle, L.R. Pease, and M. Rodriguez. (2000). Human monoclonal antibodies reactive to oligodendrocytes promote remyelination in a model of multiple sclerosis. Proc Natl Acad Sci U S A 97: 6820-6825
31. Bieber AJ, A. Warrington, K. Asakura, B. Ciric, S.V. Kaveri, L.R. Pease, and M. Rodriguez. (2002). Human antibodies accelerate the rate of remyelination following lysolecithininduced demyelination in mice. Glia 37: 241-249
32. Campagnoni AT. (1988). Molecular biology of myelin proteins from the central nervous system. J Neurochem 51: 1-14
33. Nastasijevic B, B.R. Wright, J. Smestad, A.E. Warrington, M. Rodriguez, Maher III L.J. (2012). Remyelination induced by a DNA aptamer in a mouse model of multiple sclerosis. PLoS One 7: e39595
34. Rodriguez M, D.J. Miller, and V.A. Lennon. (1996). Immunoglobulins reactive with myelin basic protein promote CNS remyelination. Neurology 46: 538-545
35. Smestad J, Maher III L.J. (2013). Ion-dependent conformational switching by a DNA aptamer that induces remyelination in a mouse model of multiple sclerosis. Nucleic Acids Res 41: 1329-1342
36. Perschbacher K, J.A. Smestad, J.P. Peters, M.M. Standiford, A. Denic, B. Wootla, A.E. Warrington, M. Rodriguez, Maher III L.J. (2015). Quantitative PCR analysis of DNA aptamer pharmacokinetics in mice. Nucleic Acid Ther 25: 11-19
37. Rhodes A, A. Deakin, J. Spaull, B. Coomber, A. Aitken, P. Life, and S. Rees. (2000). The generation, and characterization of antagonist RNA aptamers to human oncostatin M. J Biol Chem 275: 28555-28561
38. Majithia V, and S.A. Geraci. (2007). Rheumatoid arthritis: diagnosis, and management. Am J Med 120: 936-939
39. Williams RO, E. Paleolog, and M. Feldmann. (2007). Cytokine inhibitors in rheumatoid arthritis, and other autoimmune diseases. Curr Opin Pharmacol 7: 412-417
40. Salliot C, M. Dougados, and L. Gossec. (2009). Risk of serious infections during rituximab, abatacept, and anakinra treatments for rheumatoid arthritis: meta-Analyses of randomised placebo-controlled trials. Ann Rheum Dis 68: 25-32
41. Taga T, and T. Kishimoto. (1997). Gp130, and the interleukin-6 family of cytokines. Annu Rev Immunol 15: 797-819
42. Drachman DB. (1994). Myasthenia gravis. N Engl J Med 330: 1797-1810
43. Graus YF, M.H. de Baets, P.W. Parren, S. Berrih-Aknin, J. Wokke, P.J. van Breda Vriesman, and D.R. Burton. (1997). Human anti-nicotinic acetylcholine receptor recombinant Fab fragments isolated from thymus-derived phage display libraries from myasthenia gravis patients reflect predominant specificities in serum, and block the action of pathogenic serum antibodies. J Immunol 158: 1919-1929
44. Venkatesh N, S.H. Im, M. Balass, S. Fuchs, and E. Katchalski-Katzir. (2000). Prevention of passively transferred experimental autoimmune myasthenia gravis by a phage library-derived cyclic peptide. Proc Natl Acad Sci U S A 97: 761-766
45. Lee SW, and B.A. Sullenger. (1997). Isolation of a nucleaseresistant decoy RNA that can protect human acetylcholine receptors from myasthenic antibodies. Nat Biotechnol 15: 41-45
46. Hwang B, and S.W. Lee. (2002). Improvement of RNA aptamer activity against myasthenic autoantibodies by extended sequence selection. Biochem Biophys Res Commun 290: 656-662
47. Cho JS, and S.W. Lee. (2009). Sequence, and structural features of RNA aptamer against myasthenic autoantibodies. Oligonucleotides 19: 273-280
48. Hwang B, K. Han, and S.W. Lee. (2003). Prevention of passively transferred experimental autoimmune myasthenia gravis by an in vitro selected RNA aptamer. FEBS Lett 548: 85-89
49. Kim YM, K.H. Choi, Y.J. Jang, J. Yu, and S. Jeong. (2003). Specific modulation of the anti-DNA autoantibody-nucleic acids interaction by the high affinity RNA aptamer. Biochem Biophys Res Commun 300: 516-523
50. Gerard C, and B.J. Rollins. (2001). Chemokines, and disease. Nat Immunol 2: 108-115
51. Kulkarni O, R.D. Pawar, W. Purschke, D. Eulberg, N. Selve, K. Buchner, V. Ninichuk, S. Segerer, V. Vielhauer, S. Klussmann, and H.J. Anders. (2007). Spiegelmer inhibition of CCL2/MCP-1 ameliorates lupus nephritis in MRL-(Fas)lpr mice. J Am Soc Nephrol 18: 2350-2358
52. Shabgah AG, E. Fattahi, and F.Z. Shahneh. (2014). Interleukin-17 in human inflammatory diseases. Postepy Dermatol Alergol 31: 256-261
53. Ishiguro A, T. Akiyama, H. Adachi, J. Inoue, and Y. Nakamura. (2011). Therapeutic potential of anti-interleukin-17A aptamer: suppression of interleukin-17A signaling, and attenuation of autoimmunity in two mouse models. Arthritis Rheum 63: 455-466
54. Keefe AD, S. Pai, and A. Ellington. (2010). Aptamers as therapeutics. Nat Rev Drug Discov 9: 537-550